Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs
PaperCitations, authors & open-access status
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 379 citations, 2011 year and closed oa status.
379
Citations
2011
Year
closed
OA Status